FY26 Key Financial Results and Annual Report
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The report highlights a significant increase in revenue, primarily driven by a licensing agreement, and an improved loss compared to the previous year. CEO Cheryl Maley emphasized advancements in their DEP® pipeline and the company's commitment to developing targeted oncology therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- 2026 Appendix 4G and Corporate Governance Statement
- 2026 Annual Report
- Preliminary Final Report
- Becoming a substantial holder
- Ceasing to be a substantial holder
Later from Starpharma
- S&P DJI Announces September 2026 Quarterly Rebalance
- Annual General Meeting 2026 Date
- Chair and Deputy Chair Appointments
- Notification of cessation of securities - SPL
- Application for quotation of securities - SPL
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma